GlassScriptPhysician profile
Angela N Meadows
NPI 1679815609
$2,821.42
in general payments reported to CMS, 2019-2025
21 companies · $931 in 2025
The $931 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $466 · 2023: $305 · 2024: $846 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $803.31 | 2022-2025 | Micra, Selectsecure, Attain Command + Surevalve |
| Merck Sharp & Dohme LLC | $341.64 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $220.79 | 2021-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $219.01 | 2025 | Pascal |
| Abbott Laboratories | $188.22 | 2024-2025 | Jot Dx, Aveir, Esprit |
| Amgen INC. | $184.57 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $116.51 | 2021-2024 | Xarelto |
| Baxter Healthcare | $115.97 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.37 | 2021-2024 | Jardiance |
| Grt US Holding, INC. | $81.25 | 2022 | |
| Pfizer INC. | $79.24 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.82 | 2024-2025 | Lifevest |
| Esperion Therapeutics, INC. | $54.41 | 2022-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $48.73 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $41.48 | 2021-2023 | Farxiga |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $32.28 | 2022 | |
| Genentech USA, INC. | $30.10 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $29.31 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $28.16 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $19.97 | 2021 | |
| Abiomed | $18.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.